JW Pharmaceutical EBIT

The latest EBIT for 001060.KS is $110B as of June 2026. That compares with $98B in the prior-year period — up 8.1% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside JW Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 001060.KS's EBIT moved from $98B to $110B — a 8.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in JW Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, 001060.KS currently prints $110B for EBIT, while the sector average sits near $2.6T. That is roughly 95.9% below the sector mean. Large gaps often invite a closer look at JW Pharmaceutical's growth, margins, and balance sheet.

A EBIT figure of $110B for 001060.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 001060.KS's EBIT ($110B), review year-over-year change from $98B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.